ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

Completed · Not applicable

Conditions studied: Pancreas Cancer, Pancreas Cyst

In brief

Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.

Key facts

Study ID

NCT04064034

Run by

Mayo Clinic

People needed

60

Starts

2019-08-01

Expected to finish

2020-10-31

Last updated by the study team

2020-12-02

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
• Patients without pancreas cancer.
• Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.
• Healthy adults with blood specimens in an existing biobank.
• Patients with pancreatic cystic lesions.
• Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.

You may not qualify if…

• Prior treatment for pancreas cancer.
• Unable or unwilling to give consent.

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.